Anish Suri - Nov 11, 2021 Form 4 Insider Report for Cue Biopharma, Inc. (CUE)

Role
President and CSO
Signature
/s/ Anish Suri by Colin Sandercock, attorney-in-fact
Stock symbol
CUE
Transactions as of
Nov 11, 2021
Transactions value $
-$172,954
Form type
4
Date filed
11/15/2021, 04:00 PM
Previous filing
Oct 8, 2021
Next filing
Nov 17, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CUE Common Stock Options Exercise $128K +20K +21.27% $6.42 114K Nov 11, 2021 Direct F1
transaction CUE Common Stock Sale -$301K -20K -17.54% $15.07 94K Nov 11, 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CUE Stock Option (right to buy) Options Exercise $0 -20K -16% $0.00 105K Nov 11, 2021 Common Stock 20K $6.42 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on June 15, 2021.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.29, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote (2) to this Form 4.
F3 The option vests in eight equal semi-annual installments beginning September 6, 2019.